GenoMEL logo
 
 
  GenoMEL is an international research consortium coordinated by the University of Leeds.
  University of Leeds
  ???????
  ????? ????????
  ?????????
  ????????
  ?????????
  ?????????? ??????
  ?????????? ?????????
  ??????????
  Exchange Programme
 

data sharing

  Knowledge Transfer
  ????? ???????????
  Stage III Melanoma Research Group
  PharmacoGenoMEL
  ????????? ? ???????????
  ????? ???????
  ????????????? ?????
  ?????
  ???????? ???????
  ????????? ???? ?? ?????? ?????
  ???????????
  GenoMEL is an international research consortium coordinated by the University of Leeds.
  Terms and Conditions
Privacy Statement
  Translations by: Artem Vyacheslavovich Kopelev
Participants
Barcelona, Spain
 
Group Details Group Members Group Publications
 
Group Details
   

Title and address of our institution

Hospital Clinic Barcelona
IDIBAPS
Villarroel 170
08036 Barcelona
Spain

 
 

Title and address of our group

Department of Dermatology
(Clinic)
Melanoma Unit
Hospital Clinic Barcelona, IDIBAPS
Villarroel 170
08036 Barcelona
Spain

Genetics Service (Laboratory)
Hospital Clinic Barcelona, IDIBAPS
Villarroel 170
08036 Barcelona
Spain

 
 

The name, address and contact e-mail, tel of the group leader

Dr. Susana Puig, MD. PhD
Department of Dermatology
Hospital Clinic Barcelona, IDIBAPS
Villarroel 170
08036 Barcelona
Spain

E-mail: spuig@clinic.ub.es
Phone: +34 93 227 54 00 ext 2422
Fax: +34 93 227 54 38

 
 

A paragraph describing the group

The Melanoma Unit research program of the Dept. of Dermatology includes three main lines of research: 1. Genetic susceptibility to malignant melanoma and nevogenicity. Somatic genetics of melanoma and nevus development; 2. Immunotherapy and new therapies for melanoma 3. Dermoscopy, new diagnosis and prognosis techniques.

1. The melanoma group has focused particularly on the genetic aspects of the Familial Atypical Multiple Mole-Melanoma syndrome. FAMMM is an excellent example of a multi-factorial disorder in which gene-gene and gene-environment interactions play a crucial role. Our studies on a large collection of families with the FAMMM syndrome have demonstrated that 20% of the families had a mutation in the cell cycle regulator gene CDKN2A. 18% of patients with multiple primary melanomas in our setting are also carriers of CDKN2A mutations. In contrast, the incidence of mutations in sporadic melanomas is very low (1-2%). We have furthermore evaluated variants of the melanocortin 1 receptor (MC1R) gene as a modifier of melanoma risk. In addition, the role of UV light, DNA repair capacity, type of skin and degree of pigmentation in relation to melanoma risk is being investigated. Other genodermatosis and multifactorial cutaneous diseases are also investigated.

2. Our research in melanoma therapy is mainly focused on investigating new therapeutic strategies such as whole attenuated cell vaccines or autologous dendritic cell vaccines. Immunological assays are being performed to investigate host response to these vaccines and clinical trials are being developed to evaluate clinical responses. Furthermore, several therapeutic protocols of chemotherapy, biochemotherapy and/or radiotherapy are being conducted to investigate new treatment strategies.

3. Dermoscopy is a non-invasive technique focused on the diagnosis of pigmented tumors. The accuracy of melanoma diagnosis improves with the use of this technique. Special surveillance programs including total body photography and digital dermoscopy follow-up are being developed for the early diagnosis of melanoma in melanoma kindreds and in individuals with high risk to develop melanoma. Exhaustive analysis of false-negative and false-positive melanomas (by naked eye and dermoscopy), morphological description of non-melanocytic cutaneous tumors and the application of dermoscopy in non-tumoral diseases are also being investigated.

 
 

Melanoma research

In the melanoma group, lead by Professor Newton Bishop, we have studied high penetrance genes from families with multiple cases of melanoma. To investigate lower penetrance genes and the interaction between genes and the environment, we are currently recruiting a large cohort of melanoma patients, their families and matched population controls. We have also been studying patients who have relapsed with melanoma and will compare them to controls who have not relapsed in order to look at factors associated with prognosis.

 
 

Related Links

Institut de Recerca Biomèdica August Pi i Suñer (IDIBAPS)
www.idibaps.ub.edu/

Hospital Clínic de Barcelona
www.hospitalclinic.org

 
 
 
   
 
 
   
website design: NKD | email: info@NKD.org.uk | site: www.NKD.org.uk